
Thomas M Bridges

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2629740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. British Journal of Ophthalmology, 2022, 106, 288-296.	3.9	11
2	Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128479.	2.2	1
3	Discovery of the First Selective M ₄ Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacology and Translational Science, 2021, 4, 1306-1321.	4.9	11
4	Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist. ACS Medicinal Chemistry Letters, 2021, 12, 1342-1349.	2.8	6
5	Development of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2. Bioorganic and Medicinal Chemistry Letters, 2021, 53, 128416.	2.2	0
6	Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. , 2021, 62, 8.		8
7	Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126811.	2.2	3
8	Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126812.	2.2	2
9	Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacology, 2020, 45, 2219-2228.	5.4	13
10	Discovery of a novel 3,4-dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126678.	2.2	7
11	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2224-2228.	2.2	4
12	VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1714-1718.	2.2	6
13	Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1601-1604.	2.2	5
14	<i>In Vitro</i> to <i>in Vivo</i> Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology and Translational Science, 2019, 2, 442-452.	4.9	7
15	Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 362-366.	2.2	4
16	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology, 2018, 128, 492-502.	4.1	35
17	Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. , 2018, 59, 446.		35
18	Continued optimization of the M 5 NAM ML375: Discovery of VU6008667, an M 5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1356-1359.	2.2	23

#	Article	IF	CITATIONS
19	Optimization of M 4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2296-2301.	2.2	17
20	Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan -muscarinic antagonists with a novel chemotype. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2479-2483.	2.2	2
21	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2990-2995.	2.2	16
22	novel, CNS penetrant pan-muscarinic antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3576-3581.	2.2	10
23	Discovery of VU0467485/AZ13713945: An M ₄ PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. ACS Medicinal Chemistry Letters, 2017, 8, 233-238.	2.8	43
24	Challenges in the development of an M 4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 171-175.	2.2	32
25	Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. Organic Letters, 2017, 19, 5693-5696.	4.6	27
26	Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M 4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4999-5001.	2.2	15
27	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5179-5184.	2.2	17
28	Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4274-4279.	2.2	8
29	Design and Synthesis of <i>N</i> -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu ₃ NAMs. ACS Medicinal Chemistry Letters, 2017, 8, 925-930.	2.8	38
30	Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators. ACS Chemical Neuroscience, 2017, 8, 1873-1879.	3.5	13
31	Discovery and optimization of a novel series of highly CNS penetrant M 4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3- d]pyrimidine core. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3029-3033.	2.2	22
32	Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4282-4286.	2.2	11
33	Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chemical Reviews, 2016, 116, 6707-6741.	47.7	151
34	mGlu ₅ positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics, 2016, 25, 1990-2004.	2.9	48
35	Preliminary investigation of 6,7-dihydropyrazolo[1,5- a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 429-434.	2.2	7
36	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. Neuropharmacology, 2016, 102, 244-253.	4.1	23

THOMAS M BRIDGES

#	Article	IF	CITATIONS
37	Discovery of VU0409551/JNJ-46778212: An mGlu ₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Medicinal Chemistry Letters, 2015, 6, 716-720.	2.8	41
38	A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Drug Metabolism and Disposition, 2015, 43, 1718-1726.	3.3	9
39	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14078-14083.	7.1	41
40	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1310-1317.	2.2	9
41	Further optimization of the M5 NAM MLPCN probe ML375: Tactics and challenges. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 690-694.	2.2	20
42	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3515-3519.	2.2	7
43	Biased mGlu 5 -Positive Allosteric Modulators Provide InÂVivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents. Neuron, 2015, 86, 1029-1040.	8.1	121
44	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5115-5120.	2.2	5
45	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3641-3646.	2.2	7
46	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. Neuropsychopharmacology, 2014, 39, 1578-1593.	5.4	91
47	Selective Activation of M ₄ Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents. ACS Chemical Neuroscience, 2014, 5, 920-942.	3.5	116
48	M4 muscarinic acetylcholine receptor modulation of associative learning and behavioral flexibility in a novel touchscreen cognitive assessment (845.8). FASEB Journal, 2014, 28, 845.8.	0.5	0
49	Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorganic and Medicinal Chemistry Letters. 2013. 23. 346-350.	2.2	37
50	Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity. Biological Psychiatry, 2013, 73, 501-509.	1.3	95
51	Exploration of Allosteric Agonism Structure–Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu ₅) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)- <i>N</i> -(3-methyloxetan-3-yl)picolinamide (ML254). Journal of Medicinal Chemistry, 2013, 56, 7976-7996.	6.4	28
52	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. Drug Metabolism and Disposition, 2013, 41, 1703-1714.	3.3	42
53	Chemical Modification of the M ₁ Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode. ACS Chemical Neuroscience, 2012, 3, 1025-1036.	3.5	29
54	Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5084-5088.	2.2	39

THOMAS M BRIDGES

#	Article	IF	CITATIONS
55	Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6451-6455.	2.2	32
56	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 558-562.	2.2	43
57	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1972-1975.	2.2	51
58	Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5617-5622.	2.2	29
59	Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M ₁ Receptor Function in the Central Nervous System. ACS Chemical Neuroscience, 2010, 1, 104-121.	3.5	88
60	The antipsychotic potential of muscarinic allosteric modulation. Drug News and Perspectives, 2010, 23, 229.	1.5	53
61	Discovery and Characterization of Novel Allosteric Potentiators of M ₁ Muscarinic Receptors Reveals Multiple Modes of Activity. Molecular Pharmacology, 2009, 75, 577-588.	2.3	135
62	A Selective Allosteric Potentiator of the M ₁ Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. Journal of Neuroscience, 2009, 29, 14271-14286.	3.6	217
63	Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M ₄ Muscarinic Acetylcholine Receptor. ChemMedChem, 2009, 4, 1600-1607.	3.2	35
64	Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy <i>N</i> -Benzyl Isatins. Journal of Medicinal Chemistry, 2009, 52, 3445-3448.	6.4	92
65	Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5439-5442.	2.2	37
66	Application of Combinatorial Chemistry Science on Modern Drug Discovery. ACS Combinatorial Science, 2008, 10, 345-354.	3.3	206
67	G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. ACS Chemical Biology, 2008, 3, 530-541.	3.4	154
68	Centrally Active Allosteric Potentiators of the M ₄ Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 941-953.	2.5	177
69	Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Current Opinion in Molecular Therapeutics, 2008, 10, 591-601.	2.8	18
70	Molecule of the Month. Current Topics in Medicinal Chemistry, 2007, 7, 1152-1152.	2.1	0